Travel notice: Yellow fever in Nigeria | Figure 1

CDCtravel
Centers for Disease Control and Prevention

Travel notice: Yellow fever in Nigeria

Nigeria has reported an ongoing outbreak of yellow fever. Cases have been reported in at least 7 states, and a number of people have died. Anyone 9 months or older should be vaccinated against yellow fever before travel to Nigeria.

Because of a total depletion of supply of YF-Vax, the manufacturer has made an alternative yellow fever vaccine (Stamaril) available at select locations. Due to this limitation in availability, you may need to refer travelers to a yellow fever vaccine provider well in advance of travel. Visit our website (www.cdc.gov/travel) to find a Stamaril vaccination clinic.

Read more in our travel notice

More about this case

Resolved Verified literature

Why you should join Figure 1

Similar cases



Which of the following is NOT a contraindication for the yellow fever vaccine?
A. People with a thymus disorder associated with abnormal immune cell function
B. People with HIV infection with CD4 T lymphocyte values <200/mm3 or <15% of total lymphocytes for children aged <6 years
C. History of hypersensitivity to the vaccine
D. Simultaneous administration of another vaccine.
E. Infants younger than 6 months old



Researchers at Fiocruz Pernambuco have developed a new vaccine against yellow fever. Based on virus RNA, it was tested in mice and the results achieved 100% protection, even the index reached by the conventional vaccine currently offered by the Unified Health System (SUS).
Among the advantages of this new immunization is the possibility of being offered to the attenuated virus vaccine groups (children, pregnant women, elderly people, immunosuppressed persons and people with allergies to egg proteins), as well as large-scale production capacity.
The increased coverage of the DNA vaccine may be of more benefit to the population at the time of the disease outbreak, as is now the case in Brazil, where 1,170 suspected cases have been reported in six states, with deaths reported in three of them. Another advantage is that the new vaccine is safer.
According to Rafael Dhalia and Ernesto Marques (developers of the vaccine), the safety lies in the fact that the immunization is done without the presence of the live virus, even if weakened, which makes null the chance of adverse reactions and cause death by the fact of DNA is considered an inert molecule in our body. Before reaching the market, the vaccine created at Fiocruz Pernambuco needs to be tested on humans to ensure its safety and effectiveness.
Source: Oswaldo Cruz Foundation (Fiocruz).



NEW CDC Travel Health Notice: #YellowFever in Nigeria
There is a Yellow Fever (YF) outbreak in Nigeria. Travelers must be vaccinated against YF at least 10 days before travel. Some travelers may need a booster before they go. All travelers need to take steps to prevent mosquito bites.



rash from #Yellow-fever live attenuated #Vaccination



A 52-year-old man presented with a 20-minute history of chest pain radiating to the left shoulder and neck, associated with dyspnea and diaphoresis.
He had a history of hypertension, long-term smoking, and a sedentary lifestyle.
On physical examination, bibasilar crackles were noted on lung auscultation. An electrocardiogram (ECG) was performed in the primary care setting, and the patient was promptly referred to the emergency department.



A 28-year-old woman presented with a 3-day history of intense pruritus over the lower back. She reported no recent travel or exposure to new environments. She cares for a small kennel with approximately eight dogs rescued from the streets.
Physical examination revealed multiple small vesicles, some clustered and others scattered, predominantly involving the lumbar region and the left gluteal area.



A 4-month-old male infant presented with skin lesions localized to the chin for the past 3 days. Physical examination revealed multiple small pustules with surrounding inflammatory signs on the chin, along with a few scattered papules on the chest.



patient in late teens presenting after a collapse, no chest pain, no previous cardiac history, no history of sudden death in family, are there any features in this ekg that would warrant further work-up or is this just a pediatric ekg?